Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urigen Pharmaceuticals Inc.

www.urigen.com

Latest From Urigen Pharmaceuticals Inc.

Aquinox, Astellas Mull Options As Rosiptor Fails

Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business  and R&D options.

Commercial Business Strategies

Impersonal Medicine: IC/BPS And How An Orphan Indication Becomes A Common Disease

US FDA advisory committee recommendation to combine interstitial cystitis and bladder pain syndrome patients in clinical trials is an interesting example of encouraging drug development by broadening the patient population. That runs counter to the personalized medicine mantra of narrowing patient populations based on mechanism of action.

Advisory Committees Rare Diseases

Bladder Pain, Interstitial Cystitis And The Move Toward Patient-Focused Drug Development

Patients with the conditions experience the same symptoms, US FDA advisory committee concludes. Industry sponsors had advocated for combined trials, but panel did not agree with firms' recommendations on study duration and outcome measures.

Advisory Committees Clinical Trials

US FDA Weighs Whether Interstitial Cystitis Should Be Studied Separately From Bladder Pain

Advisory committee to vote on whether patients with interstitial cystitis, marked by Hunner's lesions, should be studied separately from the broader, more heterogeneous category of patients with bladder pain syndrome; recommendations could impact Aquinox and Urigen, which have drugs for IC/BPS in clinical development.

Advisory Committees Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Megabios
  • GeneMedicine
  • Valentis Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Urigen Pharmaceuticals Inc.
  • Senior Management
  • Eboo Versi, MD, PhD, CEO
    Mark J Rosenblum, CFO
    Christopher Meenan, VP, Commercial & Prod. Dev.
  • Contact Info
  • Urigen Pharmaceuticals Inc.
    Phone: (925) 280-2861
    501 Silverside Rd.
    PMB #95
    Wilmington, DE 19809
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register